Company news

Repligen Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

July 28, 2024

Repligen to Report Second Quarter 2024 Financial Results

July 15, 2024

Repligen Announces CEO Transition Plan

June 12, 2024

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

June 2, 2024

Repligen Corporation to Present at Upcoming June Investor Conferences

May 21, 2024

Repligen Reports First Quarter 2024 Financial Results

April 30, 2024

Repligen to Report First Quarter 2024 Financial Results

April 16, 2024

Repligen Appoints Maggie A. Pax to Board of Directors

March 18, 2024

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

February 20, 2024

Repligen to Report Fourth Quarter and Full Year 2023 Financial Results

February 6, 2024

Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

December 18, 2023

Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements

December 6, 2023

Repligen Announces Publication of the Company’s 2022 Sustainability Report

November 13, 2023

Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device

November 1, 2023

Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

October 30, 2023

Repligen to Report Third Quarter 2023 Financial Results

October 16, 2023

Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

October 1, 2023

Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova

September 25, 2023

Repligen Appoints Jason K. Garland as Chief Financial Officer

September 11, 2023

Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification

August 16, 2023

Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

August 1, 2023

Repligen to Report Second Quarter 2023 Financial Results

July 18, 2023

Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

May 1, 2023

Repligen to Report First Quarter 2023 Financial Results

April 17, 2023

Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum

March 13, 2023

Repligen Reports Fourth Quarter and Full Year 2022 Financial Results

February 21, 2023

Repligen Appoints Martin D. Madaus to Board of Directors

February 8, 2023

Repligen to Report Fourth Quarter and Full Year 2022 Financial Results

February 7, 2023

Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

October 31, 2022

Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands

October 31, 2022

Repligen to Report Third Quarter 2022 Financial Results

October 11, 2022

Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement

September 18, 2022

Repligen To Host Investor Day 2022

August 23, 2022

Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance

August 1, 2022

Repligen to Report Second Quarter 2022 Financial Results

July 18, 2022

Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors

May 25, 2022

Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

April 26, 2022

Repligen to Report First Quarter 2022 Financial Results

April 12, 2022

Repligen Reports Fourth Quarter and Full Year 2021 Financial Results

February 16, 2022

Repligen Launches AAV Affinity Resins for Gene Therapy Purification

February 14, 2022

Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference

February 10, 2022

Repligen to Report Fourth Quarter and Full Year 2021 Financial Results

February 2, 2022

Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

December 29, 2021

Repligen Releases Inaugural Sustainability Report

November 4, 2021

Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance

October 27, 2021

Repligen to Report Third Quarter 2021 Financial Results

October 13, 2021

Repligen Announces Agreement to Acquire Avitide Inc.

September 15, 2021

Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies

September 8, 2021

Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance

July 26, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 23 decks. Every deck is listed under its year.